New Stock News | Jingxin Pharmaceutical (002020.SZ) Files Again with the Hong Kong Stock Exchange

Zhito Finance APP has learned that, according to a disclosure by the Hong Kong Stock Exchange on September 18, Zhejiang Jingxin Pharmaceutical Co., Ltd. (referred to as Jingxin Pharmaceutical, 002020.SZ) has once again submitted an application for listing to the Main Board of the Hong Kong Stock Exchange, with CITIC Securities acting as its sole sponsor. According to the prospectus, the company is a pharmaceutical group with a strategic focus on two core therapeutic areas: (i) central nervous system (CNS) diseases; and (ii) cardiovascular and cerebrovascular diseases. As of the latest practicable date (September 10, 2026), Didaxini (Jingnuoning) is the company's only approved innovative drug. In addition to Didaxini, the company is advancing selected investigational drugs in key therapeutic areas, including JX2201, a Class 1 innovative investigational drug for the treatment of elevated lipoprotein(a) levels.